⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2715582 | 0.97 | — | — | |
| SCHEMBL994220 | 0.91 | EPHX2 (0.46) | — | |
| SCHEMBL750354 | 0.91 | METAP1 (0.40) | — | |
| SCHEMBL6127326 | 0.91 | EPHX2 (0.46) | — | |
| SCHEMBL11922743 | 0.90 | — | — | |
| SCHEMBL991936 | 0.90 | DPP4 (0.43) | — | |
| SCHEMBL750352 | 0.89 | METAP1 (0.39) | — | |
| SCHEMBL991948 | 0.89 | EPHX1 (0.42) | — | |
| SCHEMBL17347050 | 0.88 | DPP7 (0.46) | — | |
| Hydrochloric Acid SCHEMBL3512222 | 0.88 | ALDH1A1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616058-B2 | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use | ORYZON GENOMICS, S.A. (ES) | 2017-04-11 | — | — | US | claimed |
| US-20130274267-A1 | INHIBITORS FOR ANTIVIRAL USE | ORYZON GENOMICS, S.A. (ES) | 2013-10-17 | — | — | US | claimed |
| WO-2011106574-A2 | INHIBITORS FOR ANTIVIRAL USE | ORYZON GENOMICS, S.A. (ES) | 2011-09-01 | — | — | WO | claimed |
| WO-2011106105-A2 | INHIBITORS FOR ANTIVIRAL USE | ORYZON GENOMICS, S.A. (ES) | 2011-09-01 | — | — | WO | claimed |
| US-20250346567-A1 | SUBSTITUTED PYRIDINE AND PHENYL COMPOUNDS | PFIZER INC. (US) | 2025-11-13 | — | — | US | disclosed |
| EP-3716963-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD1 BINDING ANTAGONIST | Epiaxis Therapeutics Pty Ltd (AU) | 2020-10-07 | — | — | EP | disclosed |
| CN-110312522-A | - 1 inhibitor of lysine specific histone demethylation enzyme and application thereof | 堪培拉大学 | 2019-10-08 | — | — | CN | disclosed |
| CN-109121414-A | Benzopyrazole compounds and analogs thereof | 拜奥克里斯特制药公司 | 2019-01-01 | — | — | CN | disclosed |
| EP-3411411-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | Biocryst Pharmaceuticals, Inc. (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-3275861-A1 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| EP-2470500-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-6759428-B2 | SUCH AS N-((1,2)-2-(((CYANO(CYCLOPROPYL)METHYL)AMINO)CARBONYL) CYCLOHEXYL)-1H-INDOLE-2-CARBOXAMIDE; CATHEPSIN K INHIBITORS | ROCHE PALO ALTO LLC | 2004-07-06 | — | — | US | disclosed |
| US-6747053-B2 | Heteroaryl nitriles | ROCHE PALO ALTO LLC | 2004-06-08 | — | — | US | disclosed |
| US-20040077646-A1 | Indole nitriles | ROCHE PALO ALTO LLC | 2004-04-22 | — | — | US | disclosed |
| US-20030212097-A1 | Heteroaryl nitriles | ROCHE PALO ALTO LLC | 2003-11-13 | — | — | US | disclosed |
| WO-2003048123-A1 | SUBSTITUTED 2-AMINO-CYCLOALKANECARBOXAMIDES AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002064559-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-0813543-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1996028464-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |